IDenta Corp. (OTC: IDTA), a worldwide leader in the development of proprietary on-site drug, precursor of drug and explosive detection kits, today announced that the US Department of Defense (DoD) has declared IDenta as a sole-source provider of detection kits for drugs under its foreign aid program targeting the African continent. IDenta has received an initial demand under this program.

Amichai Glattstein, COO of IDenta: “We are proud with our achievement, winning approval from the US Department of Defense, as the supplier of drug detection kits to African countries under the US foreign aid program. Our sole approval by the world’s largest defense department demonstrates the quality and technological leadership of our product, and provides for an important reference to other defense, security or police forces that will consider our product in the future. We look forward to winning further orders under this DoD program.”

About IDenta Corp.

Since 2002, IDenta Corporation and its subsidiary IDenta Ltd has been recognized as a worldwide leader in the development of proprietary on-site Drug, Precursor of Drug and Explosive detection kits. IDenta develops, manufactures and distributes revolutionary products for both the professional and civil markets which consistently pass the highest qualifications and testing procedures of law enforcement and security agencies around the world.

Safe Harbor Statement

Certain of the statements contained herein may be, within the meaning of the federal securities laws, “forward-looking statements” that are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on management’s expectations as of the date hereof, and the company does not undertake any responsibility to update any of these statements in the future.

Company Contact Information:
Amichai Glattstein, COO
Tel: +972-2-5872220

Investor Relations Contact:
Ehud Helft/Gavriel Frohwein
Tel: +1-646-688-3559